Using cfDNA and ctDNA as oncologic markers: a path to clinical validation
J Dao, PJ Conway, B Subramani… - International journal of …, 2023 - mdpi.com
The detection of circulating tumor DNA (ctDNA) in liquid biopsy samples as an oncological
marker is being used in clinical trials at every step of clinical management. As ctDNA-based …
marker is being used in clinical trials at every step of clinical management. As ctDNA-based …
Enhancing Early-Stage Breast Cancer Survivorship: Evidence-Based Strategies, Surveillance Testing, and Imaging Guidelines
MJ Elliott, S Shen, DL Lam, T Brown… - American Society of …, 2024 - ascopubs.org
Addressing the challenges of survivorship necessitates a comprehensive, patient-centered
approach, focusing on mitigating risk through lifestyle modification, identifying distant …
approach, focusing on mitigating risk through lifestyle modification, identifying distant …
[PDF][PDF] Somatic Structural Variation in Breast Cancer and its Application in Longitudinal Analysis of Circulating Tumor DNA in Early Breast Cancer
MJ Elliott, K Howarth, S Main, JF Antrás, P Echelard… - sagadiagnostics.com
● Detection of circulating tumor DNA (ctDNA) following curative-intent therapy in early
breast cancer (EBC) is prognostic of disease recurrence. 1-4● Many tumor-informed ctDNA …
breast cancer (EBC) is prognostic of disease recurrence. 1-4● Many tumor-informed ctDNA …
[PDF][PDF] Longitudinal Neoadjuvant and Post-operative Evaluation of Circulating Tumor DNA in Early Breast Cancer Using a Tumor-Informed Assay: Updated Analysis of …
MJ Elliott, JF Antrás, P Echelard, A Dou, Z Veitch… - neogenomics.com
● Breast cancer is a leading cause of cancer-related death in women worldwide with
disease often diagnosed in the" early" or localized setting. 1● Many patients diagnosed with …
disease often diagnosed in the" early" or localized setting. 1● Many patients diagnosed with …